Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: A French multicentric study
- 31 May 2008
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 109 (2), 194-198
- https://doi.org/10.1016/j.ygyno.2008.01.035
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric studyAnnals Of Oncology, 2006
- The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinomaGynecologic Oncology, 2004
- Ovarian cancerBritish Journal of Cancer, 2001
- Effects of Paclitaxel on CA-125 Serum Levels in Ovarian Cancer PatientsGynecologic Oncology, 2000
- Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or PaclitaxelJournal of Clinical Oncology, 1999
- CA 125: A valid marker in ovarian carcinoma patients treated with paclitaxel?Cancer, 1996
- The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancerGynecologic Oncology, 1992
- The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreductionAmerican Journal of Obstetrics and Gynecology, 1990
- Serum Half-Life of the Tumor Marker CA 125 During Induction Chemotherapy as a Prognostic Indicator for Survival in Ovarian CarcinomaActa Obstetricia et Gynecologica Scandinavica, 1990
- The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinomaBJOG: An International Journal of Obstetrics and Gynaecology, 1989